Analysis of the clinical cure rate of Vigabatrin (Ocoda) in the treatment of infantile spasms

Vigabatrin (Vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. By inhibitingGABA breaks down and increases the concentration of the inhibitory neurotransmitter GABA in the brain, thereby effectively controlling infantile spasms (Infantile Spasms, IS) epileptic seizures. This drug is clinically considered to be one of the first-line drugs for the treatment of infantile spasms, especially for patients with spasms caused by tuberous sclerosis complex (TSC).

Clinical studies show that Vigabatrin has significant short-term efficacy in infantile spasms. The clinical response rate of monotherapy can reach 60%~70%, and some patients can significantly reduce the frequency of seizures within a few weeks of treatment, or even completely stop seizures. For TSC related infantile spasms, the efficacy is more prominent, and the cure rate or complete remission rate can be higher than that of the general group of infantile spasms patients.

In terms of long-term efficacy, the clinical cure rate of Vigabatrin is affected by many factors, including the onset age of onset, type of cause, early intervention, and combined medication. Early use of vigabatrin and control of epilepsy in the early stages of seizures can help improve neurodevelopmental outcomes and long-term control rates. Some studies have shown that patients treated early can still maintain a high seizure-free status after 1 to 2 years of follow-up, while those with delayed treatment or complicated causes have a relatively lower complete cure rate.

It should be noted that although Vigabatrin is effective in controlling convulsive seizures, some patients may still need to be treated with other anti-epileptic drugs to further improve neurological function and seizure control. At the same time, retinal function needs to be monitored regularly during the use of Vigabatrin to prevent the impact of retinal toxicity on vision. Taken together, Vigabatrin shows a high clinical remission rate and certain cure potential in the treatment of infantile spasms, making it an indispensable drug choice in clinical practice.

Reference link:https://www.drugs.com